Qiang Li

Qiang Li

Auto-generated profile, based on publicly available information

Qiang Li

The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Australia

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Stroke
Verified
Journal Article
Open access
PDF file
ZZZien Zhou
Zien Zhou
MJMeg J. Jardine
Meg J. Jardine
QLQiang Li
Qiang Li
BNBrendon L. Neuen
Brendon L. Neuen
CCChristopher P. Cannon
Christopher P. Cannon
RLRichard I. Lindley
Richard I. Lindley
Background and Purpose: Chronic kidney disease with reduced estimated glomerular filtration rate or elevated albuminuria increases risk for ischemic and hemorrhagic stroke. This study assessed the effects of sodium glucose cotransporter 2 inhibitors (SGLT2i) on stroke and atrial fibrillation/flutter (AF/AFL) from CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) and a meta-analysis of large cardiovascular outcome trials (CVOTs) of SGLT2i in type 2 diabetes mellitus. Methods: CREDENCE randomized 4401 participants with type 2 diabetes mellitus and chronic kidney disease to canagliflozin or placebo. Post hoc, we estimated effects on fatal or nonfatal stroke, stroke subtypes, and intermediate markers of stroke risk including AF/AFL. Stroke and AF/AFL data from 3 other completed large CVOTs and CREDENCE were pooled using random-effects meta-analysis. Results: In CREDENCE, 142 participants experienced a stroke during follow-up (10.9/1000 patient-years with canagliflozin, 14.2/1000 patient-years with placebo; hazard ratio [HR], 0.77 [95% CI, 0.55–1.08]). Effects by stroke subtypes were: ischemic (HR, 0.88 [95% CI, 0.61–1.28]; n=111), hemorrhagic (HR, 0.50 [95% CI, 0.19–1.32]; n=18), and undetermined (HR, 0.54 [95% CI, 0.20–1.46]; n=17). There was no clear effect on AF/AFL (HR, 0.76 [95% CI, 0.53–1.10]; n=115). The overall effects in the 4 CVOTs combined were: total stroke (HR pooled , 0.96 [95% CI, 0.82–1.12]), ischemic stroke (HR pooled , 1.01 [95% CI, 0.89–1.14]), hemorrhagic stroke (HR pooled , 0.50 [95% CI, 0.30–0.83]), undetermined stroke (HR pooled , 0.86 [95% CI, 0.49–1.51]), and AF/AFL (HR pooled , 0.81 [95% CI, 0.71–0.93]). There was evidence that SGLT2i effects on total stroke varied by baseline estimated glomerular filtration rate ( P =0.01), with protection in the lowest estimated glomerular filtration rate (<45 mL/min/1.73 m 2 ]) subgroup (HR pooled , 0.50 [95% CI, 0.31–0.79]). Conclusions: Although we found no clear effect of SGLT2i on total stroke in CREDENCE or across trials combined, there was some evidence of benefit in preventing hemorrhagic stroke and AF/AFL, as well as total stroke for those with lowest estimated glomerular filtration rate. Future research should focus on confirming these data and exploring potential mechanisms. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02065791.

6 May 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
YLYanbing Li
Yanbing Li
QLQiang Li
Qiang Li
OZOu Zhang
Ou Zhang
XGXiaonan Guan
Xiaonan Guan
YXYajun Xue
Yajun Xue
GMGuobin Miao
Guobin Miao

1 July 2008 in Journal of Affective Disorders
Verified
Journal Article
Closed access
ZZZhang-Jin Zhang
Zhang-Jin Zhang
QTQing-Rong Tan
Qing-Rong Tan
YTYao Tong
Yao Tong
QLQiang Li
Qiang Li
WKWan-Hu Kang
Wan-Hu Kang
RPRobert M. Post
Robert M. Post

28 October 2014 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
YYYumei Yang
Yumei Yang
FYFeng Yan
Feng Yan
XMXuesong Ma
Xuesong Ma
KCKaiting Chen
Kaiting Chen
NWNannan Wu
Nannan Wu
JZJinchao Zhang
Jinchao Zhang

9 July 2016 in International Journal of Stroke
Verified
Journal Article
Open access
SYSungwook Yu
Sungwook Yu
JMJanani Muhunthan
Janani Muhunthan
RLRichard Lindley
Richard Lindley
NGNick Glozier
Nick Glozier
SJStephen Jan
Stephen Jan
MHMaree L. Hackett
Maree L. Hackett
There is limited information regarding return to driving after stroke. To determine the frequency and predictors of return to driving within 1 month of acute stroke in younger (age 18–65 years) adults. POISE (Psychosocial Outcomes In StrokE) was a cohort study conducted in Australia between October 2008 and June 2010. Consecutive patients (age 18–65 years) with a recent (≤28 days) acute stroke were recruited. Validated demographic, clinical, mental health, cognitive, and disability measures including return to driving were obtained. Multivariable logistic regression was used to determine factors associated with return to driving within 1 month of stroke. Among 359 participants who were legally able to drive before stroke, 96 (26.7%) returned to driving within 1 month. Compared to those without an early return to driving (n = 263), drivers were more often male, the main income earner, in paid work before stroke and without symptoms of depression or fatigue. Independence in activities of daily living (odds ratio (OR) 30.05, 95% confidence interval (CI) 3.85–234.45), not recalling receiving advice on driving cessation (OR 5.55, 95% CI 2.86–11.11), and having returned to paid work (OR 3.93, 95% CI 1.94–7.96) were associated with early return to driving. One in four young adults resumed driving within a month, contrary to guideline recommendations. These data reinforce the importance of deciding who is responsible for determining fitness to drive after stroke, when, and whether it is reasonable to enforce driving restrictions on those with minimal disability who are fit to return to work. Australian New Zealand Clinical Trials Registry ANZCTRN 12608000459325.

16 January 2018 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
SCShiqun Chen
Shiqun Chen
YLYONG LIU
YONG LIU
Sheikh Mohammed Shariful IslamSheikh Mohammed Shariful Islam
Sheikh Mohammed Shariful Islam
HYHua Yao
Hua Yao
YZYingling Zhou
Yingling Zhou
QLQiang Li
Qiang Li
A simple noninvasive model to predict obstructive coronary artery disease (OCAD) may promote risk stratification and reduce the burden of coronary artery disease (CAD). This study aimed to develop pre-procedural, noninvasive prediction models that better estimate the probability of OCAD among patients with suspected CAD undergoing elective coronary angiography (CAG). We included 1262 patients, who had reliable Framingham risk variable data, in a cohort without known CAD from a prospective registry of patients referred for elective CAG. We investigated pre-procedural OCAD (≥50% stenosis in at least one major coronary vessel based on CAG) predictors. A total of 945 (74.9%) participants had OCAD. The final modified Framingham scoring (MFS) model consisted of anemia, high-sensitivity C-reactive protein, left ventricular ejection fraction, and five Framingham factors (age, sex, total and high-density lipoprotein cholesterol, and hypertension). Bootstrap method (1000 times) revealed that the model demonstrated a good discriminative power (c statistic, 0.729 ± 0.0225; 95% CI, 0.69–0.77). MFS provided adequate goodness of fit (P = 0.43) and showed better performance than Framingham score (c statistic, 0.703 vs. 0.521; P < 0.001) in predicting OCAD, thereby identifying patients with high risks for OCAD (risk score ≥ 27) with ≥70% predictive value in 68.8% of subjects (range, 37.2–87.3% for low [≤17] and very high [≥41] risk scores). Our data suggested that the simple MFS risk stratification tool, which is available in most primary-level clinics, showed good performance in estimating the probability of OCAD in relatively stable patients with suspected CAD; nevertheless, further validation is needed.